The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Considerations in CLL with new treatments
Florence Cymbalista, MD, PhD, of Avicenne Hospital, Bobigny, France, discusses the unanswered questions in chronic lymphocytic leukemia (CLL), including considerations with new treatments, from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain. Dr Cymbalista highlights factors surrounding the need for more long-term data, treatment sequencing and differing guidelines between countries.
